Get the Stockscreener App
14.39
0.90%
-0.13
Pre-market:
14.50
0.11
+0.76%
Kardigan Inc stock is traded at $14.39, with a volume of 862.41K.
It is down -0.90% in the last 24 hours and down -30.28% over the past month.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
See More
Previous Close:
$14.52
Open:
$14.54
24h Volume:
862.41K
Relative Volume:
1.79
Market Cap:
$1.35B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-13.78%
1M Performance:
-30.28%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$13.75
$14.54
1-Week Range:
$13.75
$18.28
52-Week Range:
$13.75
$27.00
Kardigan Inc Stock (KARD) Company Profile
Compare KARD vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KARD
Kardigan Inc
|
14.39 | 1.35B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kardigan Inc Stock (KARD) Latest News
Kardigan (KARD) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Kardigan, Inc.(NasdaqGM: KARD) added to S&P TMI Index - marketscreener.com
Kardigan (NASDAQ:KARD) Is In A Good Position To Deliver On Growth Plans - webull.com
Companies Like Kardigan (NASDAQ:KARD) Are In A Position To Invest In Growth - Moomoo
Kardigan, Inc.(NasdaqGM: KARD) added to Russell 2500 Growth Index - marketscreener.com
Kardigan (KARD) Stock Price, News & Analysis - Stock Titan
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification - Seeking Alpha
Kardigan targets genetic heart and valve diseas... - Pluang
Kardigan’s Tonlamarsen Trial Targets Severe Hypertension: What Investors Should Watch - TipRanks
Kardigan at Cantor conference: platform bet on heart drugs - Investing.com
Kardigan at Cantor conference: platform bet on heart drugs By Investing.com - Investing.com Canada
KARDKardigan Inc Short Interest - Finviz
KARD Should I Buy - Intellectia AI
Kardigan to Present at Two September Investor Conferences - Yahoo Finance
Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar - TipRanks
Kardigan (NASDAQ:KARD) Price Target Cut to $46.00 by Analysts at JPMorgan Chase & Co. - marketbeat.com
Will KARD be a Portfolio Killer in August? - Zacks Investment Research
Inside cardiovascular biotech Kardigan’s June IPO - CFO Brew
Kardigan Q2 Results: EPS misses estimates by 549.3% - scanx.trade
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates - BioSpace
Kardigan Inc. Announces Q2 2026 Financial Results and Clinical Trial Updates - Kalkine Media
Kardigan Q2 Per-Share Loss Narrows - marketscreener.com
Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary - TradingView
Earnings Flash (KARD) Kardigan Posts Q2 Loss $4.61 a Share - marketscreener.com
Kardigan: Q2 Earnings Snapshot - AOL.com
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kardigan reports Q2 2026 net loss $116.2M, cash $660.7M after IPO - TradingView
Kardigan Ord Shs (KARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kardigan (KARD) Institutional Ownership 2026 $KARD - marketbeat.com
KARD: NADetailed Earnings Estimates - Zacks Investment Research
KARD|Kardigan Ord Shs|Price:21.150|Chg%:+0.410 - TradingKey
Kardigan, Inc. Revenue Breakdown – NASDAQ:KARD - TradingView
Latest KARD ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Kardigan, Inc. (KARD) stock price, news, quote and history - Yahoo Finance UK
Price to earnings ratio of Kardigan, Inc. – NASDAQ:KARD - TradingView
Price to earnings ratio of Kardigan, Inc. – BOATS:KARD - TradingView
Kardigan, Inc. (NASDAQ:KARD) Short Interest Up ∞ in June - MarketBeat
Hrtg Pv, L.p. Net Worth (2026) - GuruFocus
Kevin Anthony Kelly Net Worth (2026) - GuruFocus
Schf Cif 2024, L.p. Net Worth (2026) - GuruFocus
Keith Bryon Johnson Net Worth (2026) - GuruFocus
Kardigan, Inc.: Target Price Consensus and Analysts Recommendations | KARD | US4859251013 - marketscreener.com
Kardigan, Inc.: Revenue and Earnings Analysts Forecasts Revisions | KARD | US4859251013 - marketscreener.com
A Quick Look at Today's Ratings for Kardigan(KARD.US), With a Forecast Between $37 to $51 - Moomoo
Kardigan (KARD) grants 20,706 RSUs tied to Perceptive-linked director pay - Stock Titan
KARD Initiated Coverage by TD Cowen -- Price Target Announced at $46 - GuruFocus
KARD News & Events - Intellectia AI
TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline - Investing.com UK
KARD Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Kardigan (KARD) Stock Forecast and Price Target 2026 $KARD - MarketBeat
Jefferies initiates Kardigan stock with buy rating on cardiology pipeline By Investing.com - Investing.com Nigeria
Kardigan Inc Stock (KARD) Financials Data
There is no financial data for Kardigan Inc (KARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Kardigan Inc Stock (KARD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Jun 22 '26 |
Buy |
16.00 |
1,250,000 |
20,000,000 |
15,042,035 |
| ARCH Venture Partners XIII, LL | Director |
Jun 22 '26 |
Buy |
16.00 |
1,250,000 |
20,000,000 |
15,042,035 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):